RNS & Investor News

Directorate changes

08 January 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announces that further to the announcement dated 5 December 2017, Richard Colin Neil Davidson CBE has been appointed as Non-Executive Chairman to the Company. Simultaneous with Mr Davidson's appointment, Adam Reynolds, as previously disclosed, has stepped down as a director of the Company.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Richard Colin Neil Davidson CBE (aged 66):

Current Appointments Appointments in the last 5 years
Bridge4 Health Limited Competition Law Process Management Limited
Bridge4 Rehabilitation Limited Eminate Limited
Cricketarchive Limited Maplewell Limited
Eclipse Film Partners No.38 LLP Persimmon Plc
Foodzeen Limited Produce Investments Plc
T S Bloor & Sons Limited Television Nottingham Limited
Testmatchextra.com Limited
The Cricketer Publishing Limited
Thixate Limited
United Church Schools Foundation Limited
United Learning Trust
WM Morrison Supermarkets Plc
Wireframe IO Limited

There is no information regarding Mr Davidson required to be disclosed under the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Jo Turner
Tel: 020 7213 0880
finnCap Broker
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001


About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.